<!DOCTYPE html>
<html>
<head>

  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta http-equiv="x-ua-compatible" content="ie=edge">
  <meta name="robots" content="noindex, nofollow">

  <title>SoloShot</title>

  <link rel="icon" href="../img/favicon.ico" type="image/x-icon">
  <link rel="stylesheet" href="../css/font-awesome.css">
<link rel="stylesheet" href="../css/techxlab.css">
  <!--[if lt IE 9]>
  <script src="https://oss.maxcdn.com/html5shiv/3.7.2/html5shiv.min.js"></script>
  <script src="https://oss.maxcdn.com/respond/1.4.2/respond.min.js"></script>
  <![endif]-->
  <script>window.pubRef = {"href":"/solutions/path-soloshot","relPath":".."};</script>
<script src="../js/jquery-1.11.3.min.js" ></script>
<script src="../js/lodash.min.js" ></script>
<script src="../js/techxlab.js" ></script>
</head>
<body>
  <div data-render-layout="main-layout"><header class="header">
  <div class="container">

    <!-- logo -->
    <a href="../"><div class="logo logo-techxlab"></div></a>

    <!-- hamburger -->
    <button class="hamburger">
      <span class="bar"></span>
      <span class="bar"></span>
      <span class="bar"></span>
    </button>

    <!-- authentication menu -->
    <ul class="navbar">
      <li class="link"><a href="../sign-up/">Sign Up</a></li>
      <li class="link"><a href="../sign-in/">Sign In</a></li>
    </ul>

  </div>
</header>

<div data-render-page="solution"><div class='solution'><div class='solution-left'>

<img src="https://techxlab.github.io/ast/141_Uniject_400pix.jpg" alt="SoloShot">

<div class='solution-contact'>
<h3>Contact Solution Provider</h3>
<div data-render-html="/solutions/path-soloshot#provider"><p>PATH<br>Seattle, WA<br>98109<br>USA<br>2062853500<br><a href="mailto:info@path.org">info@path.org</a>  </p>
</div>
</div>

</div><div class='solution-right'>

<h2>SoloShot</h2>
<h4>PATH</h4>

<div class='solution-section'>
<h3>Solution Overview &amp; Benefits</h3>
<div data-render-html="/solutions/path-soloshot"><p>Although sterile, disposable syringes and needles offer the best protection against transmission of bloodborne diseases, they are often reused in the developing world. Each year, more than 12 billion injections are administered worldwide; in developing countries 50 percent of injections are estimated to be unsafe. A primary source of transmission of disease has been the reuse of contaminated needles and syringes. To be completely safe, single-use injection devices must be designed to automatically and irrevocably inactivate after a single cycle of filling and injection. The World Health Organization/Expanded Programme on Immunization (WHO/EPI) called for the design of such devices in 1987.</p>
<p>In response to WHO’s call, PATH designed one of the first feasible approaches to nonreusable syringes for immunizations: an autodisable (AD) syringe with a fixed needle that automatically locks after a single injection. When the syringe is filled to the preset 0.5-ml level, the plunger stops and cannot be pulled back further. After the vaccine is injected, the plunger automatically locks so that the syringe and needle cannot be reused. Known as the SoloShot syringe, this technology was licensed to and is now manufactured and marketed by BD, one of the world’s leading syringe manufacturers. Third-party field validations of the device in Pakistan in the early 1990s demonstrated the acceptability and usability of the design. PATH also has assisted several other manufacturers of AD syringes to ensure a wide variety of products are available and to facilitate the lower pricing that accompanies increased competition and production volume.</p>
</div>
</div>

<div class='solution-section'>
<h3>History &amp; Development</h3>
<div data-render-html="/solutions/path-soloshot#history-and-development"><p>Since commercial introduction in 1992, 5.4 billion immunizations have been delivered using SoloShot syringes by public health programs in more than 40 countries in Africa, Asia, Eastern Europe, and Latin America. United Nations Children’s Fund—which has already distributed hundreds of millions of AD syringes to EPI programs—now provides only AD syringes to countries requesting disposable syringes, many of which are SoloShot syringes. BD has renewed its five-year licensing agreement from PATH, which allows it to supply SoloShot syringes to national and international public health agencies at low cost. The price of AD syringes is dropping rapidly and is currently within two cents of the price of disposable syringes. PATH is also assisting USAID-supported family planning agencies with the introduction of a 1-ml AD syringe to be bundled with injectable contraceptives.</p>
<p>AD syringes are now routinely used in immunization programs throughout the world. They can be used safely by vaccinators regardless of past experience or training. The devices are quicker to use than a conventional syringe and are preferred over a conventional syringe by vaccinators due to the speed and ease with which a correct vaccine dose can be drawn.</p>
</div>
</div>

<div class='solution-section'>
<h3>Availability</h3>
<div data-render-html="/solutions/path-soloshot#availability"><p>Publicly available: yes<br>Countries where available: Worldwide  </p>
</div>
</div>

<div class='solution-section'>
<h3>Specifications</h3>
<div data-render-html="/solutions/path-soloshot#specifications"><p>Dimensions: 3/8” (10 mm) to 1½” (38 mm) needle length  </p>
</div>
</div>

<div class='solution-section'>
<h3>Additional Information</h3>
<div data-render-html="/solutions/path-soloshot#additional-information"><p><a href="http://www.bd.com/pharmaceuticals/" target="_blank">Website</a><br><a href="http://www.bd.com/pharmaceuticals/products/auto-disable.asp" target="_blank">Product page</a><br><a href="https://techxlab.github.io/ast/141_TS_update_soloshot.pdf">TS_update_soloshot.pdf</a>  </p>
</div>
</div>

</div></div>
</div>

<footer class="footer">
  <div class="container container-footer">

    <!-- logos column -->
    <div class="column-left">
      <a href="../"><img src="../img/tel-logo-white.png" alt="SoloShot"></a>
      <a href="http://greatnonprofits.org/org/technology-exchange-lab-inc" target="_blank"><img src="../img/top-rated.png" alt="SoloShot"></a>
    </div>

    <!-- menu column -->
    <div class="column-center">
      <ul class="navbar navbar-footer">
        <li class="link"><a href="../prizes-and-funding/">Prizes & Funding</a></li>
        <li class="link"><a href="../faqs/">FAQs</a></li>
        <li class="link"><a href="../terms-of-service/">Terms of Service</a></li>
        <li class="link"><a href="../privacy-policy/">Privacy Policy</a></li>
      </ul>
      <p>
        The Technology Exchange Lab, Inc. | Cambridge Innovation Center<br>
        1 Broadway, 14th Floor | Cambridge, MA 02142, USA
      </p>
      <p>
        TEL is a registered non-proﬁt, tax-exempt charity under section 501(c)(3) of the U.S. Internal Revenue Code. Donations are tax deductible to the extent allowed by U.S. law. TEL is a public resource with no commercial allegiance.
      </p>
    </div>

    <!-- social -->
    <div class="column-right">
        <h3>Follow Us</h3>
        <ul class="navbar">
          <li class="link">
            <a class="icon-social facebook-white" href="https://www.facebook.com/techxlab" target="_blank"></a>
          </li>
          <li class="link">
            <a class="icon-social twitter-white" href="https://twitter.com/TechExLab" target="_blank"></a>
            </li>
          <li class="link">
            <a class="icon-social linkedin-white" href="https://www.linkedin.com/company/technology-exchange-lab-inc-" target="_blank"></a>
            </li>
          <li class="link">
            <a class="icon-social mail-white" href="mailto:contact@techxlab.org" target="_blank"></a>
          </li>
        </ul>
        <h3>Contact Us</h3>
        <a href="mailto:contact@techxlab.org">contact@techxlab.org</a>
        <h3>Subscribe to Updates</h3>
        <a class="button" href="http://eepurl.com/7GdP9" target="_blank">Sign Up ></a>
    </div>

  </div>
</footer>
</div>
</body>
</html>
